Osteomimetic matrix components alter cell migration and drug response in a 3D tumour-engineered osteosarcoma model by Pavlou, M et al.
Acta Biomaterialia xxx (xxxx) xxxContents lists available at ScienceDirect
Acta Biomaterialia
journal homepage: www.elsevier .com/locate /actabiomatFull length articleOsteomimetic matrix components alter cell migration and drug response
in a 3D tumour-engineered osteosarcoma modelhttps://doi.org/10.1016/j.actbio.2019.07.011
1742-7061/Crown Copyright  2019 Published by Elsevier Ltd on behalf of Acta Materialia Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author.
E-mail address: u.cheema@ucl.ac.uk (U. Cheema).
1 Shared Senior Authorship.
Please cite this article as: M. Pavlou, M. Shah, P. Gikas et al., Osteomimetic matrix components alter cell migration and drug response in a 3D tumou
neered osteosarcoma model, Acta Biomaterialia, https://doi.org/10.1016/j.actbio.2019.07.011M. Pavlou a,b, M. Shah a, P. Gikas c, T. Briggs c, S.J. Roberts a,d,1, U. Cheema a,1,⇑
aUCL Institute of Orthopaedics and Musculoskeletal Sciences, UCL Division of Surgery and Interventional Science, RNOH Campus, Stanmore, HA7 4LP, UK
bDepartment of Pharmacy, Faculty of Chemistry and Pharmacy, Ludwig-Maximilians University Munich, Butenandstr. 5-13, Munich 81377, Germany
cRoyal National Orthopaedic Hospital, Stanmore, HA7 4LP, UK
dDepartment of Comparative Biomedical Sciences, The Royal Veterinary College, London, NW1 0TU, UK
a r t i c l e i n f o a b s t r a c tArticle history:
Received 30 January 2019
Received in revised form 10 June 2019
Accepted 9 July 2019
Available online xxxx
Keywords:
3D model
Tumour engineering
Osteosarcoma niche
Biomimetic
DoxorubicinOsteosarcoma management continues to lack the appropriate prognostic tools to assign personalised
treatment. This leaves non-responders to standard care vulnerable to recurring disease and pulmonary
metastases. Developing 3D in vitro disease models to serve as a test bed for personalised treatment is
a promising approach to address this issue. This study describes the generation of 3D osteosarcoma mod-
els termed ‘‘tumouroids”, which are geometrically compartmentalised to reproduce the bone cancer mass
and its surrounding. Although the tumour microenvironment impacts osteosarcoma in many ways, this
model focussed on interrogating the influence of a biomimetic matrix on tumour cell behaviour. The 3D
matrix was supplemented with the bone-marrow proteins laminin, fibronectin and NuOss bone gran-
ules. This led to increased invasion of osteosarcoma cell aggregates from within the bone-like matrix into
the surrounding acellular bone marrow-like ECM. The presence of bone granules also yielded an atypical
molecular profile of osteosarcoma cells, suggesting malignant metabolic reprogramming. Changes
include decreased MMP-9 (p < 0.05) and increased PTEN (p < 0.05), MCP-1 (p < 0.01) and MCT-4
(p < 0.05) gene expression. This complex 3D biomimetic composition also changed cellular responses
to doxorubicin, a common chemotherapeutic agent used to treat osteosarcoma, and reproduced key
issues of in vivo treatment like drug penetrance and doxorubicin-induced bone toxicity. This work high-
lights the importance of a biomimetic matrix in 3D osteosarcoma models for both basic and translational
research.
Statement of Significance
This study describes the generation of 3D osteosarcoma models termed ‘‘tumouroids”, which are geomet-
rically compartmentalised to reproduce the bone cancer mass and its environment. Utilising this novel
model, specific parameters of osteosarcoma growth and invasion were investigated. Osteosarcoma cell
lines proliferate at a slower rate, exhibit malignant metabolic reprogramming, and respond to drug inter-
vention at lower concentrations of doxorubicin hydrochloride in matrix-complex compared to basic
tumouroids. As such, this study provides evidence that the tumour microenvironment impacts osteosar-
coma in many ways. The osteosarcoma tumouroid described herein may form the basis of a personalised-
medicine strategy, which will allow the testing of drug effectiveness similar to that used for antibiotic
selection for pathogenic bacteria.
Crown Copyright  2019 Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction rare and highly heterogeneous cancers, such as osteosarcoma.Many cancer patients will obtain little benefit from existing
anti-cancer treatments. This is particularly true for patients withOsteosarcoma is the most common solid tumour of bones occur-
ring predominantly within the metaphyseal medullary cavity of
long bones, with high-grade intramedullary osteoblastic osteosar-
coma the most commonly diagnosed subtype [1]. There is a grow-
ing body of evidence to suggest that mesenchymal stem cells and
their osteoblastic lineage are the cells-of-origin resulting in this
cancer [2]. Therapeutic efficacy is defined by the Huvos gradingr-engi-
2 M. Pavlou et al. / Acta Biomaterialia xxx (xxxx) xxxsystem of tumour necrosis following chemotherapy and surgical
excision, where good responders are termed those above the 90%
threshold and poor responders those below. However, this prog-
nostic system offers no insight on how to manage poor responders.
As such, there is an urgent need for an osteosarcoma personalised-
medicine modality. Whilst basic research advances our under-
standing of disease mechanisms and informs on potential drugable
signalling nodes, it stops short of informing clinicians about treat-
ment alternatives.
There is a growing appreciation of the importance of the
microenvironment and niche to the properties of cancer cells. Like
their healthy counterparts, cancer cells exist in a dynamic 3D envi-
ronment mediated by cell-to-cell and cell-to-extracellular matrix
(ECM) interactions. Cells types within the microenvironment
include osteoblasts, osteoclasts, pericytes and (other vascular cells)
and cells of the haematopoietic lineage [2]. The physical niche
includes the bone, both trabecular and cortical, and the bone mar-
row. These physical environments confer different matrix compo-
sitions, matrix architecture, oxygen levels and stiffness. Bone is a
highly vascular tissue, with a hard, mineralised matrix, mainly
composed of collagen and hydroxyapatite conferring a young’s
modulus of 15.2 GPa [3]. In comparison, bone marrow and marrow
adipose tissue are composed of collagen, fibronectin, laminin, pro-
teoglycans and hyaluronan, and a number of minor components
(Fig. 1) [4]. The young’s modulus of bone marrow varies between
0.25 and 15.7 kPa [5] and is thus much less stiff than bone. Appre-
ciation of the difference in characteristics of the bone and bone
marrow is essential when aiming to replicate in vivo biology with
an in vitro model of the disease. Indeed, bone density [6,7],
platelet-assisted intravasation [8–10], hypoxia [11,12] and matrix
composition [13,14] are all mediators of osteosarcoma develop-
ment. The research presented herein focuses on the role of the
matrix composition in the osteosarcoma niche on cancer cell
behaviour.
Through the adoption of established tissue engineering tools, a
new generation of 3D in vitro cancer models can be created via
tumour engineering. Herein we report the development of ‘tu-
mouroids’ as a novel 3D in vitro model of osteosarcoma. The aim
of this study is to create a customisable system that would allow
the interrogation of the influence of the ECM on osteosarcoma drugtrabecular bone 
bone marrow 
fibro
hyd
laminin
Fig. 1. The extracellular matrix of the osteosarcoma niche modelled in 3D tumouroids. S
marrow cavity and trabecular bone. The extracellular matrix constituents of each reg
tumouroids were designed to be geometrically compartmentalised in order to reproduce
cancer cells are in contact with. This schematic was generated using elements from the
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components of the tumour mass and matrix, namely ECM proteins,
change invasion of cancer and response to a therapeutic insult. The
‘tumouroids’ are based on the matrix protein collagen type I and
have a geometrically modular 3D structure. This compartmentali-
sation allows the composition of each module to be varied in order
to best represent the cancer mass and the organic and inorganic
features of its surrounding stroma (Fig. 1). Due to the transparency
of these cultures it is possible to track the migration/invasion of
cancer cells into the surrounding ECM as well as any changes in
cancer mass morphology. The modulation of the matrix composi-
tion of individual tumouroid compartments had an impact on the
morphological and molecular profile of cancer cells, which was
also reflected in the drug response to doxorubicin.2. Materials and methods
2.1. Cell culture
The MG-63 (ATCC CRL-1427TM) and the 143B (ATCC
CRL-8303TM) human bone osteosarcoma cell lines were purchased
from ATCC. MG-63 and 143B cells were cultured in high-glucose
Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Fisher Scien-
tific, Paisley, UK) supplemented with 10% fetal bovine serum (FBS)
(Gibco, Loughborough, UK), 1% antibiotic-antimyotic solution 100x
(Thermo Fisher Scientific, Paisley, UK) and 1% sodium pyruvate
100 mM (Thermo Fisher Scientific, Paisley, UK). Cells were main-
tained in 37 C, 5% CO2/air and 95% humidity. Cells were passaged
using TryPLETM Express (Thermo Fisher Scientific, Paisley, UK) and
then either re-plated with a seeding density of 4x104 cells/cm2 or
used directly as cell suspension for 3D tumouroid cultures.2.2. Fabrication of basic 3D tumouroid cultures
3D tumouroid cultures were generated using a customised pro-
tocol of the RAFTTM 3D cell culture system (Lonza, Slough, UK) fol-
lowing the manufacturer’s instructions. All reagents and
workflow solutions were kept on ice unless otherwise stated. Sepa-
rate solutions for the cellular artificial cancer mass (ACM) and thenectin 
roxyapatite 
collagen 
 
artificial cancer mass 
extracellular matrix 
chematic diagram of the osteosarcoma microenvironment, comprised of the bone-
ion are annotated, namely laminin, fibronectin, collagen and hydroxyapatite. 3D
the matrix composition of the bone-like matrix and the bone-marrow matrix that
Servier Medical Art database (https://smart.servier.com/).
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M. Pavlou et al. / Acta Biomaterialia xxx (xxxx) xxx 3surrounding acellular ECM were prepared consecutively. Firstly,
the cellular solution; rat-tail collagen type I 2.1 mg/ml in 0.6%
acetic acid (First Link, Wolverhampton, UK) was mixed with 10x
Minimal Essential Medium (Thermo Fisher Scientific, Paisley, UK)
and neutralised to a pH  7 using a 10 M NaOH and HEPES solu-
tion. A cell suspension was then added corresponding to 50,000
cells/gel (20.8  104 cells/ml). The collagen-MEM-cell solution
(8:1:1 ratio) was then cast in 96-well plates (240 ll/well) and
placed at 37 C for 15 min to allow gelation. Subsequently, RAFTTM
absorbers (016-1R33) were placed on the hydrogels for 15 min to
remove excess fluid and increase collagen density. 200 ll complete
media were added over each gel and the 96-well plate was kept
briefly at 37 C, 5% CO2/air, 95% humidity until the next steps.
The acellular ECM solution; collagen was mixed with 10x MEM
and neutralised as before, then supplemented with 50 lg/ml lami-
nin (Corning, Amsterdam, Netherlands). The collagen-MEM-
laminin solution was cast in 24-well plates (final volume 1.3 ml)
and before the solution polymerised, the ACM was transferred
from the 96-well plate into the centre of the 24-well plate solution
using sterile tweezers. Nested hydrogels were set at 37 C for
15 min and then compressed using RAFTTM absorbers (016-1R32)
for 15 min. This formed the final basic tumouroids (Fig. 2.A.).2.3. Fabrication of complex 3D tumouroid cultures
Complex 3D tumouroid cultures were prepared using similar
methodology as basic, with supplementation of matrix compo-
nents in the ACM and surrounding ECM. NuOss cancellous bone
granules (0.25–1 mm; Collagen Matrix Inc., Oakland, NJ USA) were
grounded under sterile conditions to a particle size < 63 lm in
diameter (Ø) using a ceramic pestle and a stainless-steel sieve
(510-4901, VWR International Ltd, Lutterworth, UK). As with basic
tumouroids, a collagen-MEM-cellular solution was prepared to
which 5 mg/ml < 63 lm Ø NuOss granules were added, mixed
and subsequently cast inside 96-well plates. The ACM hydrogels
were set at 37 C for 15 min and then compressed using RAFTTM
absorbers (016-1R33) for 5 min. The acellular collagen solution
was supplemented with 25 lg/ml laminin and 25 lg/ml fibronec-
tin (Sigma Aldrich) and cast in 24-well plates (final volume
1.3 ml). Before gelation, the ACM was transferred from the 96-
well plate into the centre of the 24-well plate solution using sterile
tweezers. The nested hydrogels were set at 37 C for 15 min and
then compressed with RAFTTM absorbers (016-1R32) for 10 min.
This formed the final complex tumouroids (Fig. 3.A.). All tumour-
oids were cultured at 37 C, 5% CO2/air, 95% humidity in 1 ml/well
DMEM and had 50% media change every 48 h.2.4. Cell proliferation
143B and MG63 basic tumouroids were prepared in triplicates
and harvested on Days 0, 3, 5 and 7 to assess proliferation in 3D.
7 days is the standard duration of tumouroid culture in this work
unless otherwise stated. Double-strand DNA (dsDNA) quantifica-
tion was carried out using the Qubit dsDNA High Sensitivity Assay
Kit (Thermo Fisher Scientific) following manufacturer’s instruc-
tions. Briefly, tumouroids were lysed in RLT buffer (Qiagen) plus
10 ll/ml b-mercaptoethanol (Sigma Aldrich) to avoid interference
of phenol-red in TRI Reagent with the fluorochrome reagent in
the Qubit kit [15]. The lysate was diluted 1/10 in nuclease-free
water (Sigma Aldrich). Readings were obtained using the QubitTM
3.0 Fluorometer and were calculated as total dsDNA [ng/ll] per
tumouroid. Growth rates were deduced using the curves of best
fit (Fig. 2.H.). Cell proliferation rates of 2D monolayers was also
performed using PrestoBlue Cell Viability Reagent (Thermo Fisher
Scientific). A standard curve was deduced on Day 0 which was thenPlease cite this article as: M. Pavlou, M. Shah, P. Gikas et al., Osteomimetic matr
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Growth rates were deduced using the curves of best fit (Fig. 2.I.).
2.5. Immunofluorescence
Tumouroids were fixed using 10% neutral buffered formalin
solution for 30 min at room temperature and then washed with
PBS (3  1 ml/well). Then tumouroids were incubated in 500 ll
4 lg/ml Phalloidin/PBS solution (P5282, Sigma Aldrich, Dorset,
UK) for 45 min at room temperature in the dark. The tumouroids
were then washed with PBS 1 ml/well and incubated in 500 ll
5 lg/ml DAPI/PBS solution (D9542, Sigma Aldrich, Dorset, UK) for
15 min at room temperature in the dark. Subsequently, the
tumouroids were washed and kept in PBS 1 ml/well until imaged
using an Apotome.2 (Carl Zeiss, Oberkochen, Germany). Z-stacks
were obtained at 10 lm intervals.
2.6. Characterisation of cell movement in 3D tumouroids
3D tumouroids were intentionally designed to have an acellular
ECM compartment surrounding the cellular ACM in order to
observe cell migration in response to matrix changes and drug
treatment. Two distinct patterns of collective cell migration were
recorded either cell sheets or invasive spheroid bodies (Fig. 2.D.).
Cell sheets were defined by a disorganised accumulation of cells
that gradually extended into the surrounding ECM (Fig. 2.C.). To
deduce a qualitative invasion profile of 143B and MG63 tumour-
oids, the following parameters were monitored at 8 fixed locations
on tumouroid circumference (Fig. 2.B.): the maximum distance of
cell sheets from the ACM margin, the maximum surface area of
invasive spheroid bodies and the total number of invasive spheroid
bodies per tumouroid. Experimental repeats per condition n > 2
and technical repeats per experiment n > 4.
2.7. Gene expression analysis
Gene expression analysis was performed in accordance with the
MIQE guidelines [16]. Total RNA was isolated from day 7 tumour-
oids; the control condition was tumouroids in a collagen-only ECM
and two test conditions were (1) basic tumouroids in a collagen-
laminin [50 lg/ml] ECM and (2) complex tumouroids with added
NuOss [5 mg/ml < 63 lm Ø] in the ACM surrounded by a
collagen-laminin [25 lg/ml]-fibronectin [25 lg/ml] ECM. TRI
Reagent (Sigma Aldrich, Dorset, UK) was used following the man-
ufacturer’s instructions for phenol/chloroform phase separation.
RNA was quantified using a NanoDrop spectrophotometer measur-
ing at 260/280 nm and 1000 ng RNA/sample were reverse tran-
scribed using the High Capacity cDNA Reverse Transcriptase Kit
(Thermo Fisher Scientific, Paisley, UK) with the program: 25 C
10 min, 37 C 120 min, 85 C 5 min, 4 C. Transcribed cDNA was
assessed via the CFX96 TouchTM Real-Time PCR (RT-PCR) Detection
System (40 cycles) using the iTaq Universal SYBR Green Supermix
(Bio-Rad, Hertfordshire, UK). Primers were designed using Pri-
mer3Plus and NCBI Primer-BLAST, specific to the Homo sapien
genes: PTEN, MMP-9, MCP-1 (also known as CCL2), VEGF-A and
MCT-4 (Table 1). Relative gene expression was calculated using
the 2-DCT method using the reference gene GAPDH, which was
ranked first as a reference gene in regard to its stability of expres-
sion in sarcomas [17].
2.8. Doxorubicin response assay
Basic and complex 3D tumouroids were cultured for 7 days to
allow invasion into surrounding ECM and were then exposed for
24 h to doxorubicin hydrochloride at concentrations 0.1 lM,
1 lM and 10 lM (n = 12 per condition), which corresponds toix components alter cell migration and drug response in a 3D tumour-engi-
o.2019.07.011
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M. Pavlou et al. / Acta Biomaterialia xxx (xxxx) xxx 5plasma Cmax 50–5000 ng/ml. To quantify cell death, tumouroids
were processed with the Qubit dsDNA High Sensitivity Assay
Kit, as previously described. To assess metabolic changes, tumour-
oids were also treated with PrestoBlue Cell Viability Reagent
(Thermo Fisher Scientific) following manufacturer’s instructions.
This Resazurin-based assay induces changes in Absorbance at
600 nm which were recorded using a Tecan Infinite 200 PRO plate
reader. To observe drug uptake in tumouroids, fluorescence imag-
ing was performed using the Apotome.2 as doxorubicin hydrochlo-
ride emits at kem 595 nm.
2.9. Statistical analysis
Data were collected from biological repeats n > 2 and technical
repeats per condition n  4. The results are presented as mean ± -
SEM. Kolmogorov-Smirnov test was performed to compare cumu-
lative distributions and determine whether subsequent analysis
required parametric or non-parametric testing. Unpaired Student’s
t test was used to compare two parametric sample populations. For
more than two populations, a one-way ANOVA and post hoc
Tukey’s multiple comparisons test was performed and for the
drug-response data analysis a two-way ANOVA with post hoc
Sidak’s multiple comparisons test was performed using GraphPad
Prism 6. (Graph-Pad, San Diego, CA). The significance level of
a = 0.05 was accepted. (p < 0.05 *, <0.01 **, <0.001 ***).
3. Results
3.1. Highly metastatic 143B cells proliferate faster in basic tumouroids
High-metastatic 143B and low-metastatic MG63 human
osteosarcoma cell lines [18] were used to form basic 3D tumouroid
cultures. They were defined as ‘basic’ due to their baseline ECM
composition of only collagen type I and laminin (Fig. 2.A.). Viabil-
ity, proliferation rate and morphological behaviour of cells in 3D
was assessed following 7–14 days of culture. Consecutive dsDNA
quantification of tumouroids revealed that both cell lines were
viable and proliferated exponentially over the 7-day culturing per-
iod. A 3-fold higher proliferation rate of 143B compared to MG63
tumouroids was recorded by day 7 (Fig. 2.H.). This is in line with
the 2-fold higher proliferation rate of 143B cells compared to
MG63 in 2D monolayers (Fig. 2.I.).
3.2. Highly metastatic 143B cells invade as larger spheroid bodies into
acellular ECM
3D cell behaviour was monitored daily using brightfield micro-
scopy and fluorescence microscopy measurements. After 7 days of
culture it was observed that both cell types in basic tumouroids
had migrated from their original seeding location, the ACM,Fig. 2. Assembly of 3D engineered osteosarcoma tumouroids and behavioural assessmen
for two collagen-based solutions to be prepared which will form the two separate co
compressed final tumouroid are indicated. This schematic was generated using elemen
diagram of the top-down view of tumouroids. The 8 fixed loci where measurements of in
images are shown, indicating how measurements of surface area and distance of invasio
ACM by day 2 and the gradual formation of a 3D cell sheet penetrating the acellular surrou
dotted line. D. Panel of representative fluorescent images showing examples of the 3D co
143B after 7 days of incubation. E. Birdseye view of MG63 and 143B basic tumouroids aft
compartment of the tumouroids. F. Qualitative assessment of the different rates of cell in
cell-sheets from the ACMmargin achieved after 14 days incubation. G. Qualitative assessm
surround, in regards to surface area of invasive bodies formed after 14 days incubation
environment with basic ECM composition over a 7 day period, via dsDNA quantificati
monolayers, using PrestoBlue and a standard curve to deduce the normalised numb
bars = standard error of mean. (For interpretation of the references to colour in this figu
3
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was apportioned to both cell proliferation and collective cell
migration. To confirm that this observation was not a displacement
effect of the overgrowing cancer cells, untransformed mesenchy-
mal stem cells (MSCs) were used to populate the ACM and were
tracked using the CM-Dil cell-tracker dye (Suppl. Fig. 1.A-B). MSCs
were used for this approach because the cell-tracker dye would
have been undetected after 24 h in the two OS cell lines due to
their high proliferation rate, which is not sufficient time to observe
invasion in the surrounding ECM. Following the standard 7 day
incubation, MSCs were imaged in the acellular ECM compartment
with both faded and intact cell-tracker dye (Suppl. Fig. 1.C-D) thus
confirming both migration and proliferation taking place in our 3D
culturing system. Two types of collective cell migration were
recorded; cell sheets (Fig. 2.B-C.) and spheroid bodies (Fig. 2.B &
2.D.). The former was defined as overlapping cell monolayers with
no apparent organisational pattern (Fig. 2.C.) whereas the latter
was defined as 3D cellular bodies with a spheroid organisation.
Invasive spheroid bodies grew either attached to the circumference
of the ACM or detached and migrated into the surrounding ECM
(Fig. 2.D.). Due to the 2 types of aggregation and invasion patterns,
and the fact that spheroid bodies were not perfect spheres, a mea-
surement of their surface area was selected to define growth. In
this 3D model, the formation of invasive spheroid bodies was asso-
ciated with an aggressive cancer phenotype and the high-
metastatic 143B cells, as these developed invasive spheroid bodies
of 359.6 ± 75 mm2 surface area. These were significantly larger
than in the low-metastatic MG63 tumouroids which generated
invasive spheroid bodies of 133.3 ± 9.7 mm2 (Fig. 2.G.).
3.3. Addition of matrix components results in enhanced cancer
invasion
Complex osteosarcoma tumouroids were so termed due to the
addition of matrix components relating to the osteosarcoma niche
i.e. the intramedullary cavity, forming a complex ECM. Finely
ground < 63 lm Ø cancellous bone granules (NuOss) were added
to the ACM and fibronectin was added to the surrounding ECM
compartment of tumouroids (Fig. 3.A.). This triggered both mor-
phological (Fig. 3.B.) and transcriptional changes (Fig. 3.G.) in
osteosarcoma cells following 7 days of incubation. The addition
of fibronectin in the acellular ECM in the absence of NuOss had
no significant effect on either the distance or surface area of invad-
ing cell bodies (Suppl. Fig. 2.A-E.). 143B complex tumouroids pro-
duced cell sheets that migrated 1180 ± 117.4 mm from the ACM and
3.7 ± 0.5 invasive bodies per tumouroid, which was significantly
greater than their basic counterparts (Fig. 3.C.). MG63 complex
tumouroids also showed a trend for increased stromal invasion
as they developed cell sheets 800 ± 64.2 mm far from the ACM,
however no other parameters showed significant change (Fig. 3.D.).t. A. Schematic diagram of basic tumouroid production indicating the requirement
mpartments of the final tumouroid. The dimensions of the compressed ACM and
ts from the Servier Medical Art database (https://smart.servier.com/). B. Schematic
vasion were performed are marked in red-dotted squares. Representative Brightfield
n were recorded. C. Panel of the chronological aggregation of 143B cells within the
nding for time points 1, 2, 3, 5 and 7 days. The ACMmargin is annotated by a white-
llective cell invasion patterns, cell-sheets and spheroid bodies, formed by MG63 and
er 7 days of incubation. These are collages of single fluorescence images of the ACM
vasion between 143B and MG63 into a basic ECM surround, in regards to distance of
ent of the different rates of cell invasion between 143B and MG63 into a basic ECM
. H. Quantitative assessment of cell proliferation of MG63 and 143B cells in a 3D
on. I. Quantitative assessment of cell proliferation of MG63 and 143B cells in 2D
er (No) of cells. ACM = artificial cancer mass; ECM = extracellular matrix; error
re legend, the reader is referred to the web version of this article.)
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Fig. 3. Formation and characterisation of complex tumouroids. A. Schematic diagram of complex tumouroid production indicating the requirement for two collagen-based
solutions to be prepared which will form the two separate compartments of the final tumouroid. The solution used to make the ACM is supplemented with NuOss granules
(<63 lm ø) and the solution used to make the surrounding ECM is supplemented with Fibronectin. The dimensions of the compressed ACM and compressed final tumouroid
are disclosed. This schematic was generated using elements from the Servier Medical Art database (https://smart.servier.com/). B. Panel of representative fluorescent images
showing examples of morphological modifications occurring to the 3D collective cell invasion patterns depending on the ECM composition of tumouroids. Both MG63 and
143B tumouroids are shown after 7 days of incubation. The ACM margin is indicated by a white dotted line and annotation. C. Effect of basic and complex 3D matrix
composition on 143B cell invasion, in regards to distance of cellsheets from ACMmargin. D. Effect of basic and complex 3D matrix composition on 143B cell invasion, in terms
of invasive bodies per tumouroid. E. Effect of basic and complex 3D matrix composition on MG63 cell invasion, in regards to distance of cellsheets from ACMmargin. F. Effect
of basic and complex 3Dmatrix composition on MG63 cell invasion, in terms of invasive bodies per tumouroid. G. Birdseye view of MG63 and 143B complex tumouroids after
7 days of incubation. These are collages of single fluorescence images of the ACM compartment of the tumouroids. For the 143B complex tumouroid the number of invasive
bodies are marked with an orange dotted line and numbered. For the MG63 complex tumouroid the periphery of the cell sheet in marked with an orange dotted line. The ACM
margin in both tumouroids is indicated by a yellow dotted line. H. Relative changes in transcript levels of selected genes from cells cultured in 2D 143B monolayers compared
to 3D collagen after 7 days incubation. Data shown as DCt normalised to reference gene GAPDH. I. Relative changes in transcript levels of selected genes from cells cultured in
2D MG63 monolayers compared to 3D collagen after 7 days incubation. Data shown as DCt normalised to reference gene GAPDH. J. Relative changes in transcript levels of
selected genes from 143B 3D tumouroids without added NuOss (basic) and 3D tumouroids with added NuOss (complex) after 7 days incubation. Data shown as DDCt after
first normalising to reference gene GAPDH and then to transcript levels obtained from 3D collagen-only tumouroids. (ns = not significant, p < 0.05=*, p < 0.01=**,
p < 0.001=***). K. Relative changes in transcript levels of selected genes from MG63 3D tumouroids without added NuOss (basic) and 3D tumouroids with added NuOss
(complex) after 7 days incubation. Data shown as DDCt after first normalising to reference gene GAPDH and then to transcript levels obtained from 3D collagen-only
tumouroids. (ns = not significant, p < 0.05=*, p < 0.01=**, p < 0.001=***). ACM = artificial cancer mass; ECM = extracellular matrix; error bars = standard error of mean. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Table 1
RT-PCR primers.
Gene Forward Primer (50 to 30) Reverse Primer (50 to 30) size
PTEN AATGTTCAGTGGCGGAACTTGC CACACACAGGTAACGGCTGAGG 140
MMP9 TTCTGCCCGGACCAAGGATA ACATAGGGTACATGAGCGCC 109
MCP1 TCAAACTGAAGCTCGCACTCT CATTGATTGCATCTGGCTGAG 119
VEGFA GTGAATGCAGACCAAAGAAAGA CTCCAGGGCATTAGACAGCA 148
MCT4 CCACATCAAAGGGATCTTCTGC CCATCCTCCATCCAGGGTTTT 100
M. Pavlou et al. / Acta Biomaterialia xxx (xxxx) xxx 73.4. Increased matrix complexity shifts osteosarcoma gene expression
towards metabolic reprogramming
To further investigate the changes associated with increasing
matrix complexity, the expression of selected genes that govern
processes linked to osteosarcoma aggression [18] were assessed
via real-time quantitative PCR (RT-qPCR) and correlated to mor-
phological observations. Initially, the change in transcript levels
of certain genes in response to culturing 143B and MG63 cells in
3D collagen instead of 2Dmonolayers was assessed. Indeed the dif-
ference was striking, as the expression of the gelatinase enzyme
matrix metalloproteinase-9 (MMP9) increased by 37-fold
(p < 0.01), vascular endothelial growth factor (VEGF) increased by
4.9-fold (p < 0.0001) and phosphatase and tensin homolog (PTEN)
decreased by 0.5-fold (p < 0.001) in the highly metastatic 143B
3D cultures compared to monolayers (Fig. 3.H.). Culturing MG63
in 3D cultures increased MMP9 by 2.4-fold (p = 0.05), PTEN by
1.6-fold (p < 0.001) and decreased VEGF by 0.57-fold (p < 0.0001)
(Fig. 3.I.). Comparing the transcript levels of cells from the two dif-
ferent tumouroid compositions revealed greater changes for 143B
tumouroids (Fig. 3.J.). Indeed, a 28-fold (p < 0.05) decrease in the
MMP-9 expression was measured in complex tumouroids. Further-
more, a 5-fold (p < 0.01) increase in expression of monocyte
chemoattractant protein-1 (MCP-1) and a 1.2-fold (p < 0.05)
increase of PTEN expression, which has an inverse relation to
MMP-9, was also apparent when comparing complex to basic
tumouroids. Although VEGF expression displayed no significant
difference between complex and basic 143B tumouroids, there
was a significant 1.8-fold (p < 0.05) increase in complex MG-63
tumouroids compared to basic (Fig. 3.K.). Both 143B and MG-63
complex tumouroids displayed a significant increase in monocar-
boxylate transporter 4 (MCT-4) expression, by 1.5-fold (p < 0.05)
and 1.4-fold (p < 0.05), respectively.3.5. Increasing matrix complexity alters drug response of osteosarcoma
cells in 3D
Having confirmed that a complex environment, which repli-
cates aspects of the bone intramedullary cavity, causes a shift
towards an aggressive osteosarcoma phenotype in both tested cell
lines, the effect of the commonly used anthracycline drug doxoru-
bicin on 3D basic and complex tumouroids was tested. Doxorubicin
is an antibiotic derived from Streptomyces peucetius [19], which has
a mechanism of action involving DNA intercalation, blockage of
DNA biosynthesis by stabilising the topoisomerase II complex thus
preventing DNA replication [20] and increase of cytotoxicity by
free-radical production [19]. Initially, to understand how the
osteosarcoma cell lines behaved when exposed to doxorubicin,
confluent 2D cultures of 143B and MG63 cells were exposed to 5
increasing drug concentrations (0.1–10 lM) for 24 h (Fig. 4.A-C.).
Quantification of dsDNA indicated that there was significantly
(p < 0.0001) more cell death in 143B than MG63 monolayers with
respect to untreated cells (Fig. 4.B.). As doxorubicin intercalates in
the DNA replication fork of dividing cells, 143B monolayer cultures
may be more vulnerable to its effect as they replicate 3-times fas-Please cite this article as: M. Pavlou, M. Shah, P. Gikas et al., Osteomimetic matr
neered osteosarcoma model, Acta Biomaterialia, https://doi.org/10.1016/j.actbiter than MG-63 (Fig. 4.A.). Similarly, the PrestoBlue assay revealed
a greater degree of metabolic change in 143B cells compared to
MG63 for most tested concentrations of doxorubicin (Fig. 4.C.).
The next step was to test the hypothesis that complex tumour-
oids, which replicated the tumour microenvironment, would
respond differently to doxorubicin and potentially more like that
observed clinically. Cells in basic and complex ECM were cultured
for 7 days and subsequently treated with 0.1, 1 and 10 lM doxoru-
bicin hydrochloride for 24 h (Fig. 4.D-G.). Comparing the rate of cell
deathwith respect to untreated tumouroids revealed that, although
not statistically significant, 143B tumouroids in complex ECMwere
more resistant to drug treatment at concentrations 0.1 and 1 lM.
Treatment with 10 lM doxorubicin lead to more cell death in com-
plex 143B tumouroids (Fig. 4.D). As anticipated from the qPCR
(Fig. 3.G.) and 2D drug assay (Fig. 4.B-C), the complex 143B tumour-
oids underwent a significantly (p < 0.0001) higher change in meta-
bolic activity than basic tumouroids in response to doxorubicin
(Fig. 4.E.). A similar observation was made for MG63 tumouroids
as complex ECM composition resulted in a trending but not signif-
icant increase of metabolic activity after drug-treatment (Fig. 4.G.).
Interestingly, the low-metastatic MG63 cells showed a trend,
although not significant, resilience to doxorubicin-induced cell
death when in the complex ECM (Fig. 4.F.).4. Discussion
Herein, a geometrically compartmentalised 3D model of
osteosarcoma was developed, which was composed of a core
ACM and a surrounding acellular ECM compartment. Key material
aspects were incorporated into the 3D model in the form of solid
bone granules and bone-marrow matrix proteins to enable the
investigation of cancer cell invasion patterns and drug responses
in a biologically relevant environment.
The application of 3D models in cancer research has grown in
the last two decades [21,22], with promising approaches being
borrowed from tissue engineering [23–26] to provide in vitromod-
els with both biological relevance and high-throughput potential
for drug-screening; e.g. 3D tumour spheroids [27] and the
hanging-drop method [28]. Several of these approaches have cast
new light on basic cancer biology and re-emphasised how the
tumour microenvironment dictates cancer fate [29,30]. As the field
progresses for most epithelial cancers, rare cancers such as
osteosarcoma have been marginalised in terms of novel drug dis-
covery and preclinical model development. Indeed, although
in vitro osteosarcoma models have been reported and reviewed
for their relevance to the disease in vivo [31], most models are
either scaffold-free, to provide flexibility, or are scaffold-based to
provide the 3D structure – none combine both. The geometrically
compartmentalised tumouroids described herein combine flexibil-
ity and 3D structure. This provides the opportunity to study how
the matrix component of the stroma, which was developed to
reproduce the physical niche in bone, changes cancer invasion
and drug response.
Collagen type I is the most prevalent ECM protein in bone and
its increased expression and linearised fibrils have been associatedix components alter cell migration and drug response in a 3D tumour-engi-
o.2019.07.011
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sive cancer cells have a higher affinity for matrices expressing the
collagen type I peptide motif GFOGER (where O = hydroxyproline)
and laminin-111 motif IKVAV [33], the components of our basicPlease cite this article as: M. Pavlou, M. Shah, P. Gikas et al., Osteomimetic matr
neered osteosarcoma model, Acta Biomaterialia, https://doi.org/10.1016/j.actbtumouroid cultures. Collagen-based hydrogels have a restricted
stiffness range which can limit applications for preclinical
osteosarcoma research [34,35]. Through the use of the compres-
sion technique collagen hydrogels were generated with an averageix components alter cell migration and drug response in a 3D tumour-engi-
io.2019.07.011
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strength of 0.6 ± 0.11 MPa with modulus of 1.5 ± 0.36 MPa [37],
along with an 48-fold increase in protein density to 120 mg/ml
[38]. Although this may not approximate the physiological proper-
ties of bone, the plastic compression method has been shown to
promote cell proliferation and migration, which is expected of stiff
matrices [39]. Bone with osteosarcoma, like its healthy counter-
part, undergoes constant remodelling and dynamic homeostasis
during which transformed osteoblasts/MSCs deposit pre-
mineralised osteoid composed of 95% collagen type I. As such, it
was considered an appropriate baseline substrate for priming
physiological osteosarcoma behaviour.
A specific organisation of cells in 3D and distinct migration pat-
terns were recorded in tumouroids. High-metastatic 143B tumour-
oids with basic matrix composition (collagen I + laminin) formed
cell clusters in the ACM by day 2 and then invaded the surrounding
acellular ECM by day 5 of culture, predominantly as cell sheets
(Fig. 2.C.). The equivalent low-metastatic MG63 tumouroids exhib-
ited similar behaviour. Previous work on collective sheet-like
migration described this as a modular control system; boundary
cells are converted into pioneers while the rest of the cells trace
and follow the pattern of pioneers through cell-cell coordination
in a growth-factor independent manner [40].
Both 143B and MG63 tumouroids exhibited another collective
cell migration pattern in the form of 3D invasive bodies with a
spheroid-like morphology. These irregular spheroids grew either
attached to the ACM or detached and migrated into the surround-
ing acellular ECM (Fig. 2.D.). High-metastatic 143B tumouroids
produced significantly larger spheroids compared to the low-
metastatic MG63 cultures (Fig. 2.G.). This was apportioned to the
3-fold higher proliferation rate (Fig. 2.H.) and the high metastatic
potential of 143B cells [18]. The generation of spheroids may also
be key when evaluating patient-derived osteosarcoma tumouroids
since a similar pattern of cell migration in colorectal cancer report-
edly acted as an independent indicator of distant metastases and
poor survival [41]. It is important to highlight that although other
hallmarks of cancer are missing from this model, the introduction
of a biomimetic matrix in 3D in vitro was sufficient to induce phe-
notypes that are linked to in vivo.
Within the complex osteosarcoma model described herein, the
material properties of the biomimetic ‘bone’ compartment con-
taining collagen, cancer cells and NuOss bone granules are differ-
ent to the biomimetic ‘bone marrow’ component that is the
collagen-laminin-fibronectin surround. Indeed, the addition of
NuOss bone granules most likely made the ACM stiffer. Although
outside of the remit of this study, it is interesting to note that inva-
sion of both the 143B and MG63 cells in 3D, at least in terms of
sheet invasion, was significantly greater when NuOss granules
were introduced to the ACM (Supp. Fig. 3.A-E.). The vast majority
of studies have described the phenomenon of durotaxis, where
cells move to the stiffest part of 3D gels [42]. In stark contrast toFig. 4. Analysis of cell sensitivity to doxorubicin treatment in basic and complex tumou
treated for 24 h with increasing doxorubicin concentrations. B. Quantitative assessment o
increasing doxorubicin concentrations, using dsDNA quantification. C. Quantitative asses
treatment with increasing doxorubicin concentrations, using PrestoBlue metabolic assay
complex ECM after 24 h treatment with increasing doxorubicin concentrations, using dsD
tumouroids with basic or complex ECM after 24 h treatment with increasing doxorubicin
death rate in 3D MG63 tumouroids with basic or complex ECM after 24 h treatment with
assessment of metabolic change rate in 3D MG63 tumouroids with basic or complex ECM
metabolic assay. H. Birdseye view of MG63 and 143B tumouroids with basic and complex
These are collages of single live/dead fluorescence images of the ACM compartment of tu
penetrance in the 3D cancer masses. I. Live/dead stained image of the lower left ACM qu
Invasive spheroid body is asterisk-marked and magnified to emphasise the cell death o
matrix; error bars = standard error of mean.
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neered osteosarcoma model, Acta Biomaterialia, https://doi.org/10.1016/j.actbithis, the current study reveals that osteosarcoma cell invasion is
significantly enhanced (Fig. 3.C-E.) where a reverse stiffness gradi-
ent exists, in that cells embedded in a stiff ‘bone-like’ matrix,
invade faster into a ‘softer’ surrounding matrix. This likely confirms
that the observations made in the current study are indeed inva-
sion, as opposed to cell migration, and that invasive pathways
are playing a significant role in the morphology of invasion
(Fig. 3.B & 3.G.), as well as the rate (Fig. 3.C-E.).
The plasticity of osteosarcoma cells in response to changes in
their surrounding matrix was recorded both morphologically, in
terms of the invasion profile, and molecularly via qPCR. Matrix
supplementation with NuOss bone granules led to increased inva-
sive bodies in high-metastatic 143B tumouroids (Fig. 3.D.) and
appeared to hinder their migration into the surrounding ECM
(Fig. 3.E.). This was also reflected by low MMP-9 expression
(Fig. 3.J.). Although osteosarcoma in vivo has been associated with
high levels of MMP [43–46], cancer growth and invasion within
this 3D model could be portrayed by a switch to protease-
independent collective cell migration [47]. LowMMP-9 levels could
also have been the result of high PTEN expression in complex 143B
tumouroids (Fig. 3.J.), since PTEN expression hinders MMP-9 pro-
moter activity via TNFa [48]. In the context of osteosarcoma, PTEN
inhibits tumour-induced osteoclast differentiation to counteract
bone resorption [49]. As such, PTEN upregulation in complex
143B tumouroids containing NuOss bone granules would be an
expected result of the elevated levels of MCP-1 (Fig. 3.J.). MCP-1
is an early stress response signal [50] which in osteosarcoma trig-
gers osteoclastogenesis from monocytes and attracts osteoclasts to
the cancer site in order to resorb the surrounding bone [51]. This is
in agreement with previous reports that 143B cells can produce
osteolytic tumours in vivo [52] due to the inherent malignancy pro-
file of the immortalised cell line [51]. The addition of NuOss
caused 143B tumouroids to upregulateMCT-4 (Fig. 3.J.), suggesting
that the cancer cells shifted towards a glycolytic metabolismwhich
is linked to poor cancer patient survival [53]. As gate-keeper of lac-
tate efflux, MCT-4 upregulation could also reflect the in vivo phe-
nomenon of transformed MSCs promoting osteosarcoma
migration via lactate [54]. This is however an observation based
on the expression of a single gene of the glycolytic switch and more
extensive molecular analysis would be required to fully elucidate
matrix induced metabolic reprogramming. It should be noted that
on the whole a divergent gene expression profile was observed
when comparing MG63 to 143B cells, which has been documented
before [55], and is likely to reflect the differences in osteosarcoma
characteristics. Indeed, as we specifically chose genes linked to
metastasis, this further confirms that the complex tumouroid is
likely to be facilitating the cells natural capacity for metastasis.
The 3D tumouroids described herein were created to interro-
gate the effects of a biomimetic matrix on osteosarcoma behaviour.
A limitation of these models is the lack other key elements of the
tumour microenvironment such as neovascularisation and interac-roids. A. Panel of live/dead fluorescence images of 2D 143B and MG63 monolayers
f cell death rate in 2D monolayers of 143B and MG63 cells after 24 h treatment with
sment of metabolic change rate in 2D monolayers of 143B and MG63 cells after 24 h
. D. Quantitative assessment of cell death rate in 3D 143B tumouroids with basic or
NA quantification. E. Quantitative assessment of metabolic change rate in 3D 143B
concentrations, using PrestoBlue metabolic assay. F. Quantitative assessment of cell
increasing doxorubicin concentrations, using dsDNA quantification. G. Quantitative
after 24 h treatment with increasing doxorubicin concentrations, using PrestoBlue
ECM. Tumouroids were incubated for 7 days and treated with doxorubicin for 24 h.
mouroids in order to provide a visual representation of cell death and doxorubicin
adrant of a 143B tumouroid in basic ECM after treatment with 10 lM doxorubicin.
ccurring mostly on the periphery. ACM = artificial cancer mass; ECM = extracellular
ix components alter cell migration and drug response in a 3D tumour-engi-
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between pioneer cancer cells and follower cells within a metasta-
sising tumour in vivo, obtaining analogous morphological and
molecular diversity within tumouroids illustrates an improved bio-
logical relevance.
To test the capacity of tumouroids as a drug screening platform
we exposed complex and basic high metastatic 143B tumouroids
to doxorubicin after an initial 7 day culture period. It was hypoth-
esised that osteosarcoma cells cultured in the complex 3D matrix
would infer a distinct drug response compared to cells within a
basic matrix. To experimentally test this hypothesis, day 7 tumour-
oids were exposed to 0.1–10 mM doxorubicin hydrochloride for
24 h. This corresponds to 50–5000 ng/ml doxorubicin, which
includes the range of plasma Cmax (39.8 ± 15.3 to 630.4 ± 22.1
ng/ml) achieved in individuals with normal body surface area
(BSA) after a 24 h infusion [56].
Analysis of the doxorubicin treated tumouroids revealed 143B
cells grown in the complex matrix composition underwent a
greater rate of change in metabolic activity than basic tumouroids
in response to doxorubicin (Fig. 4.E.) whereas MG63 complex
tumouroids only trended to an increased rate of metabolic change
at 1 lM (Fig. 4.G.). Furthermore, the complex ECM composition
conferred a trend for resistance to drug-induced death in both cell
lines compared to the basic ECM counterparts (Fig. 4.D. & 4.F.). At
the highest drug dose, 143B complex tumouroids had a greater rate
in cell death, which may indicate the requirement for higher drug
doses or more efficient doxorubicin-like drugs clinically. 143B cells
have already been shown to generate drug-resistant tumours
in vivo [57,58], confirming that complex 3D tumouroids are cap-
able of reproducing aspects of cancer cell behaviour in vitro. Qual-
itative observations of live-dead stained tumouroids with basic
and complex ECM composition indicated that the majority of cell
death existed in the periphery of the ACM (Fig. 4.H.) and invasive
bodies (Fig. 4.I.). Following the paradigm of a protective cancer
core and limited drug penetrance in vivo, this observation is not
surprising. The cells at the periphery are exposed to the drug for
longer time periods hence are more susceptible to cell death.5. Conclusions
The potential mechanisms through which osteosarcoma
achieves chemoresistance have been reviewed extensively [59],
concluding that both the intrinsic cellular profile and the extracel-
lular environment impact cancer cell behaviour. To our knowledge,
the complex osteosarcoma tumouroids described herein are the
first geometrically modular 3D cultures to incorporate matrix com-
ponents of the osteosarcoma niche, and capture the adaptive nat-
ure of tumour cells in response to changes in their surroundings
and drug treatment. It is envisaged that this body of work will
engage the field and generate the impetus for further development
of biomimetic osteosarcoma models.Acknowledgements
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